dc.contributor
Institut Català de la Salut
dc.contributor
[Paesano N] Department of Surgery, Universitat Autònoma de Barcelona, Bellaterra, Spain. Clínica Creu Blanca, Barcelona, Spain. [Catalá V, Tcholakian L] Clínica Creu Blanca, Barcelona, Spain. Uroima, Barcelona, Spain. [Alomar X, Barranco MÁ] Clínica Creu Blanca, Barcelona, Spain. [Hernández-Mancera J] Fundació Puigvert, Barcelona, Spain. [Miró B] Unitat d’Estadística i Bioinformàtica, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Trilla E, Morote J] Department of Surgery, Universitat Autònoma de Barcelona, Bellaterra, Spain. Servei d’Urologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Tcholakian, Larisa
dc.contributor.author
Alomar, Xavier
dc.contributor.author
Barranco, Miguel Ángel
dc.contributor.author
Hernández Mancera, Jonathan
dc.contributor.author
Paesano, Nahuel
dc.contributor.author
Catalá, Violeta
dc.contributor.author
Miro, Berta
dc.contributor.author
Enrique, Trilla Herrera
dc.contributor.author
Morote Robles, Juan
dc.date.accessioned
2025-05-03T13:35:59Z
dc.date.available
2025-05-03T13:35:59Z
dc.date.issued
2025-03-31T10:10:59Z
dc.date.issued
2025-03-31T10:10:59Z
dc.date.issued
2025-01-31
dc.identifier
Paesano N, Catalá V, Tcholakian L, Alomar X, Barranco MÁ, Hernández-Mancera J, et al. Validation of the Barcelona Magnetic Resonance Imaging Predictive Model for Significant Prostate Cancer Detection in Men Undergoing Mapping per 0.5 Mm-Core Targeted Biopsies of Suspicious Lesions and Perilesional Areas. Cancers (Basel). 2025 Jan 31;17(3):473.
dc.identifier
http://hdl.handle.net/11351/12847
dc.identifier
10.3390/cancers17030473
dc.identifier
001418329700001
dc.identifier.uri
http://hdl.handle.net/11351/12847
dc.description.abstract
Detection; Prostate biopsy; Prostate cancer
dc.description.abstract
Detecció; Biòpsia de pròstata; Càncer de pròstata
dc.description.abstract
Detección; Biopsia de próstata; Cáncer de próstata
dc.description.abstract
Background/Objectives: Validation of predictive models (PMs) is crucial to be implemented in new populations or when advances in diagnostic approaches occurred. The aim of this study is to validate the BCN-MRI PM for sPCa when a highly effective prostate biopsy protocol is used. Methods: A prospective cohort of 457 men suspected of having PCa, for whom MRI results were reported with the Prostate Imaging-Reporting and Data System (PI-RADS) v 2.1, underwent a per 0.5 mm-core mapping targeted biopsy of suspicious lesions and perilesional areas, followed by a 12-core-systematic biopsy. These procedures took place between 1 February 2022, and 29 February 2024, at a reference center for prostate biopsy. The individual likelihood of sPCa was assessed through the BCN-MRI risk calculator. Results: The overall sPCa detection rate was 58.3%. The calibration curve of the BCN-MRI PM showed an appropriate accuracy between expected and observed probabilities with a discrimination ability for sPCa yielding an area under the curve (AUC) of 0.862 (95% CI 0.828–0.896) comparable to the AUC of 0.858 (95% CI 0.833–0.883) observed in the development cohort. The application of the BCN-MRI PM provided a net benefit over performing biopsies on all men, avoiding 24.9% of prostate biopsies at 95% sensitivity for sPCa, compared to the 23.7% reduction observed in the development cohort. Conclusions: We conclude that the BCN-MRI PM is ready to be implemented when this biopsy protocol is employed.
dc.description.abstract
This research was supported by the Instituto de Salut Carlos III (SP) and the European Union (PI20/01666).
dc.format
application/pdf
dc.relation
Cancers;17(3)
dc.relation
https://doi.org/10.3390/cancers17030473
dc.rights
Attribution 4.0 International
dc.rights
http://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Pròstata - Càncer - Diagnòstic
dc.subject
Imatgeria per ressonància magnètica
dc.subject
DISEASES::Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Genital Neoplasms, Male::Prostatic Neoplasms
dc.subject
Other subheadings::Other subheadings::/diagnosis
dc.subject
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Diagnostic Techniques and Procedures::Clinical Laboratory Techniques::Cytological Techniques::Cytodiagnosis::Biopsy::Image-Guided Biopsy
dc.subject
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Diagnostic Techniques and Procedures::Diagnostic Imaging::Tomography::Magnetic Resonance Imaging
dc.subject
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias urogenitales::neoplasias de los genitales masculinos::neoplasias de la próstata
dc.subject
Otros calificadores::Otros calificadores::/diagnóstico
dc.subject
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::técnicas y procedimientos diagnósticos::técnicas de laboratorio clínico::técnicas citológicas::citodiagnóstico::biopsia::biopsia guiada por imágenes
dc.subject
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::técnicas y procedimientos diagnósticos::diagnóstico por imagen::tomografía::imagen por resonancia magnética
dc.title
Validation of the Barcelona Magnetic Resonance Imaging Predictive Model for Significant Prostate Cancer Detection in Men Undergoing Mapping per 0.5 Mm-Core Targeted Biopsies of Suspicious Lesions and Perilesional Areas
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
